Emma Walmsley

Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 15, 2022
Adult, Chest pain, Cancer, Gulf Cooperation Council, Pain, Expense, U.S. Securities and Exchange Commission, Security (finance), Back pain, Constipation, Splenomegaly, Abdominal pain, Cough, Safety, United Kingdom, Sickle cell disease, United Arab Emirates, Company, Indigestion, Time, Marketing, Research, IRAK4, Annual report, Emma Walmsley, Private Securities Litigation Reform Act, Patient, Ministry, Operating cost, Incidence, Net, Headache, GCC, Marginal cost, Extremities, Food, Kingdom, Regulation of tobacco by the U.S. Food and Drug Administration, OTCQX, Nausea, Pharmaceutical industry, Income, Health, Q3, Glutamine

TORRANCE, Calif., Nov. 14, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its results of operations and financial condition as of and for the three and nine months ended September30, 2022 and provided a business update.

Key Points: 
  • TORRANCE, Calif., Nov. 14, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its results of operations and financial condition as of and for the three and nine months ended September30, 2022 and provided a business update.
  • Net revenues in Q3 2022 increased by $0.7 million, or nearly 15%, from Q2 2022 net revenues of $4.3 million.
  • Total operating expenses in Q3 2022 decreased slightly from Q2 2022 due to $0.3 million decrease in selling expenses.
  • Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease.

Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 15, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Nausea, Cough, Sickle cell disease, Splenomegaly, United Kingdom, Constipation, United Arab Emirates, Private Securities Litigation Reform Act, Incidence, Indigestion, Gulf Cooperation Council, Security (finance), Research, Annual report, Pain, Net, Cancer, Emma Walmsley, Marketing, Patient, Abdominal pain, Kingdom, COVID-19, Company, Chest pain, IRAK4, Ministry, Diverticulosis, Safety, Loss, Headache, Operating cost, Back pain, Expense, Extremities, Time, Food, Adult, Kainos, OTCQX, Pharmaceutical industry, Income, Glutamine, Health, Q2

TORRANCE, Calif., Aug. 15, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update.

Key Points: 
  • TORRANCE, Calif., Aug. 15, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update.
  • Net revenues in Q2 2022 increased by $1.1 million, or nearly 33%, from Q1 2022 net revenues of $3.2 million.
  • Loss from operations in Q2 2022 decreased by $1.6 million, or 53.1%, from $3.1 million in Q1 2022 as a result of the increase in net revenues in Q2.
  • Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease.

Emmaus Life Sciences Reports Third Quarter Financial Results and Business Highlights

Retrieved on: 
Friday, November 12, 2021
Education, Constipation, Chest pain, Security (finance), National Health Regulatory Authority, Food, Extremities, Lymphoma, COVID-19, Cancer, Splenomegaly, Pain, MYD88, Review, Drug, Expense, Safety, Food and Drug Administration, Kainos, Trial of the century, Research, Diverticulosis, Travel, Headache, U.S. Securities and Exchange Commission, Sickle cell disease, Time, Marketing, Gulf Cooperation Council, Patient, United Arab Emirates, FDA, Adult, SCD, Private Securities Litigation Reform Act, Ministry, NHRA, Mutation, Kingdom, Back pain, Application, Prescription, SEC, Cough, Leukemia, Nausea, Telehealth, OTCQX, Annual report, Partnership, Period, Incidence, Article 13, Indigestion, Emma Walmsley, Abdominal pain, Health insurance, Pharmaceutical industry, Animal, Cryptocurrency

TORRANCE, Calif., Nov. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the quarter and nine months ended September 30, 2021.

Key Points: 
  • TORRANCE, Calif., Nov. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the quarter and nine months ended September 30, 2021.
  • Asembia will provide a single point of contact for benefits investigation, financial and co-pay assistance, as well as patient and provider education.
  • Net revenues declined 6% compared to the second quarter of 2021 primarily due to lower bulk orders in the third quarter than in the second quarter.
  • Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease.

Microsoft holds annual shareholders meeting

Retrieved on: 
Wednesday, December 4, 2019
Businesspeople, Companies, Business, Satya Nadella, Telugu people, Microsoft, Emma Walmsley

REDMOND, Wash., Dec. 4, 2019 /PRNewswire/ -- Speaking to shareholders at Microsoft Corp.'s annual meeting on Wednesday, Chief Executive Officer Satya Nadella outlined Microsoft's opportunity and responsibility: to help its customers and partners thrive in a world where every company is a technology company and to create technology that benefits everyone on the planet, including the planet itself.

Key Points: 
  • REDMOND, Wash., Dec. 4, 2019 /PRNewswire/ -- Speaking to shareholders at Microsoft Corp.'s annual meeting on Wednesday, Chief Executive Officer Satya Nadella outlined Microsoft's opportunity and responsibility: to help its customers and partners thrive in a world where every company is a technology company and to create technology that benefits everyone on the planet, including the planet itself.
  • "I am proud of how we are helping organizations across industries innovate and thrive using our platforms and tools," Nadella said.
  • Executive Vice President and Chief Financial Officer, Amy Hood, reported that Microsoft executed well in fiscal year 2019 and reported a strong start to the current fiscal year.
  • The following proposals were acted on by the company's shareholders at the meeting:
    Re-elected 12 directors and elected one new director: Emma Walmsley, chief executive officer of GSK, to serve until the next annual meeting of shareholders.

Microsoft announces board changes and proposes election of new board member

Retrieved on: 
Thursday, September 19, 2019
Companies, Industries, Business, Emma Walmsley, Microsoft, Walmsley, GlaxoSmithKline, MSFT

REDMOND, Wash., Sept. 19, 2019 /PRNewswire/ --Microsoft Corp. on Wednesday announced the nomination of Emma Walmsley, CEO of GlaxoSmithKline (GSK) and member of the GSK board, to the Microsoft board of directors.

Key Points: 
  • REDMOND, Wash., Sept. 19, 2019 /PRNewswire/ --Microsoft Corp. on Wednesday announced the nomination of Emma Walmsley, CEO of GlaxoSmithKline (GSK) and member of the GSK board, to the Microsoft board of directors.
  • Walmsley will be presented for election at the company's annual shareholders meeting, which will be held Dec. 4, 2019.
  • If Walmsley and the rest of the company's nominees are elected, Microsoft's board of directors will consist of 13 members, including John W. Thompson, Microsoft independent board chair; WilliamH.
  • Microsoft (Nasdaq "MSFT" @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge.